SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Ciprofibrate-d_6

Item No. 33917

CAS Registry No.: 2070015-05-1
Formal Name: 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-d_3-propanoic-3,3,3-d_3 acid
Synonyms: (±)-Ciprofibrate-d_6, WIN 35,833-d_6
MF: $C_{13}H_8Cl_2D_6O_3$
FW: 295.2
Chemical Purity: ≥95% (Ciprofibrate)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_6); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ciprofibrate-d_6 is intended for use as an internal standard for the quantification of ciprofibrate (Item No. 18515) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Ciprofibrate-d_6 is supplied as a solid. A stock solution may be made by dissolving the ciprofibrate-d_6 in the solvent of choice, which should be purged with an inert gas. Ciprofibrate-d_6 is soluble in acetonitrile, methanol, and DMSO.

Description

Ciprofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα; EC_{50} = 0.9 µM in a transactivation assay).[1] It is selective for PPARα over PPARγ and PPARδ at 300 µM.[2] Ciprofibrate (250 µM) induces cell cycle arrest at the G_2/M and S phases in Fao rat, but not HepG2 human, hepatocellular carcinoma cells.[3] It decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia when administered at a dose of 10 mg/kg.[4] Formulations containing ciprofibrate have been used in the treatment of hypertriglyceridemia.

References

1. Quang, T.H., Ngan, N.T.T., Minh, C.V., *et al.* Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii. *Bioorg. Med. Chem. Lett.* **22(7)**, 2527-2533 (2012).
2. Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. *Proc. Natl. Acad. Sci. USA* **94(9)**, 4312-4317 (1997).
3. Passilly, P., Jannin, B., Hassell, S.J., *et al.* Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry. *Exp. Cell. Res.* **223(2)**, 436-442 (1996).
4. Bighetti, E.J.B., Patricio, P.R., Casquero, A.C., *et al.* Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. *Lipids Health Dis.* **8**, 50 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM